Stocks / INCY
INCY stock forecast
INCYTE CORP · Healthcare · Biotechnology
The model's rating
Greatly Outperform
INCY is rated Greatly Outperform as of September 29, 2026: its medium-term return forecast is in the top fifth of the stocks the model scores.
Create a free account to compare any two stocks; the numeric score is part of Premium.
INCY is not among the 20 largest holdings published for 2026 Q4. See the portfolio
INCY against the S&P 500
| Period | INCY | S&P 500 (SPY) |
|---|---|---|
| 1 month | -1.5% | -0.3% |
| 3 months | +6.6% | +2.5% |
| Year to date | +22.9% | +12.7% |
| 1 year | +43.1% | +15.7% |
Total return, dividends included.
Key numbers
| Price | $121.35 |
| Market cap | 24.6 Billion |
| P/E (trailing 12 months) | 14.9 |
| P/S (trailing 12 months) | 4.2 |
| P/B (latest quarter) | 4.2 |
| Gross margin | 92.6% |
| Net profit margin | 27.7% |
| Return on equity | 29.6% |
| Beta | 0.5 |
As of July 28, 2026.
INCY and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| TECH | BIO-TECHNE CORP | 11.36 Billion | Greatly Underperform | INCY vs TECH |
| MRNA | MODERNA INC | 76.88 Billion | Greatly Underperform | MRNA vs INCY |
| REGN | REGENERON PHARMACEUTICALS INC | 78.07 Billion | Greatly Outperform | REGN vs INCY |
| VRTX | VERTEX PHARMACEUTICALS INC | 132.51 Billion | Outperform | VRTX vs INCY |
Questions
What does the Upfront Investment model say about INCY?
The model rates INCYTE CORP (INCY) "Greatly Outperform" as of September 29, 2026, which means its medium-term return forecast is in the top fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the INCY rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is INCY in the Upfront Investment model portfolio?
INCY is not among the 20 largest holdings published for 2026 Q4.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.